Myoblast and fibroblast derived small extracellular vesicles differentially affect myoblast migration dynamics
Hagemann KN., McColl RS., Lovett JAC., Snyman C., Myburgh KH.
Animal Study, published in J Muscle Res Cell Motil (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Muscle Res Cell Motil (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40824483
- PMCID
- PMC12717140
- DOI
- 10.1007/s10974-025-09705-y
Abstract (original English)
Muscle injury activates satellite cells and fibroblasts, with extracellular vesicles (EVs) mediating the related intercellular communication. The influence of EVs released by either cell type on recipient cell behaviour is still unclear. This study investigated the uptake and effects of EVs derived from C2C12 myoblasts (myo-EVs) and L929 fibroblasts (fibro-EVs) on proliferating myoblasts. Both cell lines were cultured in media largely depleted of FBS-derived EVs. Myo-EVs and fibro-EVs isolated from conditioned media were characterised using conventional methods. Effects of these EVs on myoblast function were assessed via PKH67-labelled EV uptake, proliferation, scratch closure, leading front migration rate and individual cell trajectories and western blot analysis for MyoD and Myogenin. Myoblasts preferentially internalised myo-EVs at 5 h (myo-EVs: 3.41 ± 1.34 vs fibro-EVs: 1.25 ± 1.13 puncta per cell) and 48 h (myo-EVs 16.55 ± 12.60 vs fibro-EVs 9.67 ± 4.88) (both p < 0.05). Under proliferative EV-depleted conditions, added EVs did not change myoblast proliferation. However, the elevated expression of Myogenin indicating a subtle shift toward differentiation. Myo-EVs increased myoblast migration rate into a scratch, compared to controls (13.77 ± 1.7 vs 11.08 ± 2.23 µm/h, p < 0.01), but had no effect under conditions of FBS EV depletion. On the other hand, fibro-EVs increased t
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.